Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities

EOJ Porta, K Kalesh, PG Steel - Frontiers in pharmacology, 2023 - frontiersin.org
Chagas disease is a vector-borne illness caused by the protozoan parasite Trypanosoma
cruzi (T. cruzi). It poses a significant public health burden, particularly in the poorest regions …

Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets

M Laureano de Souza, TJWJD Lapierre… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Chagas disease (CD) imposes social and economic burdens, yet the available
treatments have limited efficacy in the disease's chronic phase and cause serious adverse …

Leaf hydroalcoholic extract and oleoresin from Copaifera multijuga control Toxoplasma gondii infection in human trophoblast cells and placental explants from third …

AFF Martínez, SC Teixeira, G de Souza… - Frontiers in Cellular …, 2023 - frontiersin.org
The conventional treatment of congenital toxoplasmosis is mainly based on the combination
of sulfadiazine and pyrimethamine. However, therapy with these drugs is associated with …

Antimicrobial peptides (AMPs): potential therapeutic strategy against trypanosomiases?

M Rojas-Pirela, U Kemmerling, W Quiñones… - Biomolecules, 2023 - mdpi.com
Trypanosomiases are a group of tropical diseases that have devastating health and socio-
economic effects worldwide. In humans, these diseases are caused by the pathogenic …

Resveratrol and curcumin for Chagas disease treatment—a systematic review

CHL Imperador, CB Scarim, PL Bosquesi, JR Lopes… - Pharmaceuticals, 2022 - mdpi.com
Chagas disease (CD) is a neglected protozoan infection caused by Trypanosoma cruzi,
which affects about 7 million people worldwide. There are two available drugs in …

Euphane and Tirucallane Triterpenes with Trypanocidal Activity from Euphorbia desmondii

MB Saidu, G Krstić, A Barta, A Hunyadi… - Journal of Natural …, 2024 - ACS Publications
The phytochemical investigation of Euphorbia desmondii resulted in the isolation of 15
previously undescribed triterpenoids (desmondiins A, CP) and 8 already described …

Natural endoperoxides as promising anti-leishmanials

D Sarkar, L Monzote, L Gille, M Chatterjee - Phytomedicine, 2024 - Elsevier
Background The discovery of artemisinin, an endoperoxide, encouraged the scientific
community to explore endoperoxides as potential anti-parasitic molecules. Although …

The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

H Berhe, M Kumar Cinthakunta Sridhar, M Zerihun… - Pharmaceutics, 2024 - mdpi.com
Chagas disease and leishmaniasis are both neglected tropical diseases that affect millions
of people around the world. Leishmaniasis is currently the second most widespread vector …

RCB-4, a novel cyclic peptide, from Ricinus communis with anti-Trypanosoma cruzi activities

F Galossi-de-Souza, LP de Carvalho… - Journal of Molecular …, 2024 - Elsevier
Introduction Chagas disease and toxoplasmosis caused by parasites Trypanosoma cruzi
and Toxoplasma gondii affect more than 28 million people in poor areas of Latin America …

[PDF][PDF] Antimicrobial Peptides (AMPs): Potential Therapeutic Strategy against Trypanosomiases? Biomolecules 2023, 13, 599

M Rojas-Pirela, U Kemmerling, W Quinones… - 2023 - academia.edu
Trypanosomiases are a group of tropical diseases that have devastating health and
socioeconomic effects worldwide. In humans, these diseases are caused by the pathogenic …